GT Biopharma Announces $7.1 Million Convertible Debt Financing
11:18 AM January 23, 2018LOS ANGELES, January 23, 2018 /PRNewswire/ — GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris: GTBP.PA) today announced that it has entered into definitive agreements for a private placement of convertible notes and warrants for gross proceeds of $7,055,000. The company intends to use the proceeds from the financing to advance its immuno-oncology programs, which are based on the company’s proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for
Read more